Drugs / Pyramax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05633420 | Jul → Sep 2022 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04783051 | May 2021 → Jun 2022 | Plasmodium falciparum malaria | University of Kinshasa | Completed | Met primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-01-20 | Shin Poong Pharmaceutical Co. Ltd. | EMA에서 승인받은 국내신약16호 Pyramax® 3상 임상시험 보고서 shinpoong.co.kr ↗ |
| 2014-01-20 | Shin Poong Pharmaceutical Co. Ltd. | 복합성분 말라리아 치료제 “피라맥스정”(PYRAMAX) 신약 허가 shinpoong.co.kr ↗ |
| 2014-01-20 | Shin Poong Pharmaceutical Co. Ltd. | 피라맥스(PYRAMAX) 관련, 완제(정제) 제조소 및 원료의약품(API) 제조소, 각각 EU-GMP 승인 인증획득 shinpoong.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyramax | “Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)” NCT04783051 ↗ |
| Known as | pyronaridine-artesunate | “Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)” NCT04783051 ↗ |